bis(2-chloro-1-methylethyl) ether: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 7944 |
| CHEMBL ID | 1403227 |
| CHEBI ID | 82409 |
| SCHEMBL ID | 380464 |
| MeSH ID | M0149135 |
| Synonym |
|---|
| propane,2'-oxybis[1-chloro- |
| bis(2-chloro-1-methylethyl) ether |
| (2-chloro-1-methylethyl) ether |
| nsc-2849 |
| nci-c50044 |
| wln: g1y1 & oy1 & 1g |
| dcip (nematocide) |
| .beta.,.beta.'-dichlorodiisopropyl ether |
| 108-60-1 |
| 2,2-dichloroisopropyl ether |
| bis(.beta.-chloroisopropyl) ether |
| 2,2'-dichlorodiisopropyl ether |
| dichlorodiisopropyl ether |
| dichloroisopropyl ether |
| 2,2'-dichloroisopropyl ether |
| ether, bis(2-chloro-1-methylethyl) |
| nsc2849 |
| bis(2-chloro-1-methylethyl)ether, technical grade |
| 2,2'-oxybis(1-chloropropane) |
| propane, 2,2'-oxybis[1-chloro- |
| NCGC00091739-01 |
| isopropylchlorex |
| brn 1735833 |
| bis(beta-chloroisopropyl)ether |
| ai3-18183 |
| einecs 203-598-3 |
| ccris 91 |
| bis(beta-chloroisopropyl) ether |
| bis(1-chloro-2-propyl) ether |
| nemamort |
| rcra waste no. u027 |
| rcra waste number u027 |
| nemamol |
| un2490 |
| propane, 2,2'-oxybis(1-chloro- |
| hsdb 503 |
| nemamorte |
| nsc 2849 |
| bis(2-chloro-1-methylethyl)ether |
| 1-chloro-2-(1-chloropropan-2-yloxy)propane |
| MLS002454389 |
| smr001372005 |
| NCGC00091739-02 |
| AKOS006273379 |
| C19350 |
| HMS3039J11 |
| dtxcid40167 |
| cas-108-60-1 |
| dtxsid4020167 , |
| NCGC00258753-01 |
| tox21_201201 |
| 0jjz8ler32 , |
| dichloroisopropyl ether [un2490] [poison] |
| unii-0jjz8ler32 |
| (2-chloro-1-methylethyl) ether [hsdb] |
| bis(2-chloro-1-methylethyl)ether [iarc] |
| CHEBI:82409 , |
| SCHEMBL380464 |
| di-(1-chloro-2-propyl)-ether |
| 1-chloro-2-(2-chloro-1-methylethoxy)propane # |
| CHEMBL1403227 |
| J-002167 |
| bis-(2-chloroisopropyl) ether, analytical standard |
| bis-(2-chloroisopropyl) ether |
| bis-(2-chloro-1-methylethyl) ether |
| bis-(2-chloro-1-methylethyl) ether 2000 microg/ml in methanol |
| bis-(2-chloro-1-methylethyl)-ether |
| Q2184481 |
| Class | Description |
|---|---|
| ether | An organooxygen compound with formula ROR, where R is not hydrogen. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 0.0336 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 7.9433 | 0.0010 | 19.4141 | 70.9645 | AID588537 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 39.8107 | 0.0398 | 16.7842 | 39.8107 | AID995 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 23.1093 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 29.8493 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nucleoplasm | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nuclear body | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| chromatin | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nucleus | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.18) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||